Pierre Thadee Victor Kemula, Chief Financial Officer at AgomAb Therapeutics, bought AGMB on Oct 6, 2026

Data as of Oct 16

▲ BUY$26K3,000 shares at $8.67Pierre Thadee Victor Kemula Chief Financial OfficerAGMB AgomAb Therapeutics NV

Watch AGMB

Traded: Oct 6, 2026
Disclosed: Oct 7, 2026
Filed: 1 day after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

AGMBSimilar stocks (XLV — its sector index fund), rebased to AGMB's price on the disclosure day

AGMB since disclosure

−5.9%

Similar stocks (XLV) since disclosure

+4.7%

XLV — its sector index fund

Change in closing price from Oct 7, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

⚪ 3+ insiders buy after a 30% drop — fired on this trade
Not enough evidence · In past tests: 8.0 percentage points better than similar stocks over 3 months · 2,952 tries
⚪ CFO buys $25K+ of own stock — fired on this trade
Not enough evidence · In past tests: 3.6 percentage points better than similar stocks over 3 months · 2,178 tries
⚪ CFO buys $25K+ of own liquid stock — fired on this trade
Not enough evidence · In past tests: 2.0 percentage points better than similar stocks over 3 months · 1,426 tries

What this rule is doing with AGMB right now

See pricing →

Already a member? Sign in

Other trades in the same filing

▲ BUYPierre Thadee Victor Kemula Chief Financial OfficerAGMB AgomAb Therapeutics NV$42.9Kdisclosed Oct 7 · filed 1 day after the trade 3 rules fired
▲ BUYPierre Thadee Victor Kemula Chief Financial OfficerAGMB AgomAb Therapeutics NV$17.1Kdisclosed Oct 7 · filed 1 day after the trade 3 rules fired

See every trade on AGMB →